Market leaders and major investment banks turn to WilmerHale for capital markets legal advice and business advantage. In 2021, we handled more than 80 public offerings, Rule 144A placements, PIPE financings, and other equity and debt capital markets transactions, raising in excess of $40 billion for leading companies in life sciences, technology, financial services and various other industries. Since 2011, we have served as counsel in nearly 600 capital markets transactions with total proceeds of more than $250 billion. In addition, our capital markets lawyers routinely advise clients on a wide variety of debt financing transactions, including term loans, working capital facilities, acquisition financing, liability management transactions and recapitalizations. We have one of the leading IPO practices in the United States—as both issuer counsel and underwriters’ counsel—with particular experience in IPOs by high-growth, entrepreneurial companies in a range of life sciences and technology sectors. Download the PDF to see a selection of our recent capital markets transactions.
Recent Capital Markets Transactions: 2022
Recent Capital Markets Transactions: 2022
Publication
Related Documents
Related Solutions
- Capital Markets
- Corporate Governance and Disclosure
- Cross-Border Transactions
- Financial Services
- FinTech
- Life Sciences
- Technology
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
A premier corporate governance and disclosure practice providing timely, tailored and practical advice to public company clients based on in-depth experience and insight.
WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.
WilmerHale has played a leading role in shaping the rules that govern the financial services industry in the United States.
Representing FinTech clients throughout their lifecycles.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Critical industry insight and formidable strength across key practices.